Deciphera Pharmaceuticals Inc Stock News

DCPH earnings call for the period ending March 31, 2020.

Microsoft today unveiled the Surface Book 3, its "most powerful laptop ever," starting at $1,599, available for preorder now, and shipping on May 21.

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -6.25% and -97.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended March 31, 2020 and provided an update on clinical and corporate developments.

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 5.) Arcturus Therapeutics Ltd (...

Fund reveals 1st-quarter trades Continue reading...

Deciphera (DCPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Director Michael Douglas Taylor sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an a

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Universal Health (UHS), Deciphera Pharmaceuticals (DCPH)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Universal Health ( UHS – Research Report ), Deciphera Pharmaceuticals ( DCPH – Research Report ) an

Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Hormel Foods, Tyson Foods and Zebra Technologies, on Wednesday. HIGHLIGHTS

In a report released today, Andrew Berens from Leerink Partners maintained a Hold rating on Deciphera Pharmaceuticals ( DCPH – Research Report ), with a price target of $55.00 . The company’s shar

Stocks Analysis by Harry Boxer covering: MGM Resorts International, Fluor Corporation, Builders FirstSource Inc, Avadel Pharmaceuticals PLC. Read Harry Boxer's latest article on Investing.com

A closely watched drug candidate didn't meet the primary endpoint of a late-stage trial, which creates a wide-open opportunity for a competitor.